Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
March 11, 2019
Celyad to Host R&D Day and Webcast on Monday, March 18 in New York City
MONT-SAINT-GUIBERT, Belgium, March 11, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of ...
March 11, 2019
Saniona initiates Phase 2a Tesomet clinical study in hypothalamic obesity patients
Saniona (SANION.ST), a biotech company focused on the central nervous system and eating disorders, announced today that it has recruited the first patient in a ...
March 11, 2019
Orphazyme to present at Cowen & Co Annual Health Care Conference
Copenhagen, Denmark, March 11, 2019 – Orphazyme A/S (ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced that Anders ...
March 11, 2019
Spring Bank Pharmaceuticals Reports 2018 Fourth Quarter and Full-Year Financial Results and Corporate Highlights
HOPKINTON, Mass., March 11, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral ...
March 11, 2019
Yuhan Corp and Sorrento Therapeutics Announce Completion of Phase 1 Clinical Study of Anti-PD-L1 Antibody IMC-001
SEOUL, South Korea and SAN DIEGO, March 11, 2019 (GLOBE NEWSWIRE) -- Yuhan Corporation (000100.KS; Yuhan) and Sorrento Therapeutics, Inc. (SRNE) announced today that ImmuneOncia, ...
March 11, 2019
Athenex, Inc. Announces Fourth Quarter and Year Ended December 31, 2018 Financial Results and Provides Corporate Update
BUFFALO, N.Y., March 11, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies ...
March 11, 2019
RedHill Biopharma to Present at the 31st Annual ROTH Conference
TEL-AVIV, Israel and RALEIGH, N.C., March 11, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty ...
March 11, 2019
Orchard Therapeutics Announces Acceptance of OTL-200 Abstract for MLD at the 45th Annual Meeting of the European Society for Blood and Bone Marrow Transplantation (EBMT)
BOSTON and LONDON, March 11, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with ...
March 11, 2019
Arrowhead Pharmaceuticals Begins Dosing in Phase 1 Study of ARO-APOC3 for Treatment of Hypertriglyceridemia
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (ARWR) today announced that it has dosed the first subjects in a Phase 1 clinical study of ARO-APOC3, an RNAi-based ...
March 11, 2019
Tyme Technologies To Present at the Oppenheimer 29th Annual Healthcare Conference on March 20, 2019
NEW YORK, March 11, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing metabolic-based cancer therapies, announced that management will present ...
March 11, 2019
Eiger BioPharmaceuticals Management Team to Present and Participate in Jefferies HBV Investor Summit
PALO ALTO, Calif., March 11, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare ...
March 11, 2019
aTyr Pharma Announces Research Collaboration With Global Biotherapeutics Leader CSL Behring
SAN DIEGO, March 11, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based ...
March 11, 2019
VBL Therapeutics to Present at the Society of Gynecologic Oncology (SGO) 50th Annual Meeting on Women's Cancer on March 18
TEL AVIV, Israel, March 11, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of ...
March 11, 2019
ProQR Doses First Patient in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2
LEIDEN, Netherlands and CAMBRIDGE, Mass., March 11, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of ...
March 11, 2019
Soleno Therapeutics to Participate in Two Upcoming Investor Conferences
REDWOOD CITY, Calif., March 11, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of ...
March 11, 2019
Pfenex Reports Fourth Quarter and Full Year 2018 Results and Provides Business Update
SAN DIEGO, March 11, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) is a clinical-stage development and licensing biotechnology company focused on leveraging its ...
March 11, 2019
CymaBay Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
NEWARK, Calif., March 11, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies ...
March 11, 2019
Zosano Pharma Announces Presentation and Participation at the 31st Annual Roth Conference
FREMONT, Calif., March 11, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (ZSAN), a clinical-stage biopharmaceutical company, today announced that its chairman, president and chief executive ...
March 6, 2019
Nicox Announces 2018 Financial Results and 2019 Milestones
March 6, 2018 - release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced the ...
March 6, 2019
Zealand Pharma doses first patient in Phase 3 trial with dasiglucagon for the treatment of congenital hyperinsulinism
Copenhagen, March 6, 2019 – Zealand Pharma A/S ("Zealand") (ZEAL.CO), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today ...
Page 38 of 169